A study in mice suggests the diabetes drug acarbose can reshape bacterial sugar metabolism, boosting short-chain fatty acids and limiting weight gain on a high-sucrose diet.
A diabetes drug best known for blunting blood sugar spikes may also have a second life as a microbiome-shaped anti-obesity treatment, according to a study published in iScience. Researchers in Japan report that acarbose can change the way gut bacteria handle sucrose, turning ordinary table sugar into a more favourable substrate for short-chain fatty acid production and, in mice, reducing weight gain on a high-sugar diet.
The work helps explain a long-standing puzzle around acarbose and a related drug, miglitol. Both belong to the alpha-glucosidase inhibitor class and act in the intestine, but earlier work from the same group suggested that miglitol had a stronger effect on microbial fermentation and incretin hormones such as GLP-1 and GIP. The new study, led by Hayato Yoshikawa and Takashi Miki at Chiba University, shows that acarbose does more than block host digestion: it also reaches certain bacteria and interferes with their own maltose-processing machinery.
In laboratory experiments, the researchers found that acarbose enters Escherichia coli through the LamB transport channel and is then carried deeper into the cell by a maltodextrin transporter. Once inside, it disrupts two enzymes central to bacterial carbohydrate metabolism, causing maltose handling to stall and downstream energy pathways to falter. Another alpha-glucosidase inhibitor, voglibose, did not produce the same effect, suggesting that acarbose has a more specific interaction with bacterial sugar-processing systems than the class label alone would imply.
The sugar that matters most, however, appears to be sucrose. The team showed that a sucrose porin in Klebsiella pneumoniae can also move acarbose into the cell, but the outcome depends on the carbohydrate environment: the drug suppressed growth on maltose, yet in sucrose it did not inhibit bacteria and instead appeared to aid growth. That distinction proved important in mice. When acarbose was given with sucrose, portal vein levels of short-chain fatty acids rose, GIP secretion fell and GLP-1 increased. With maltose, the hormonal effect was far weaker.
The clearest anti-obesity effect emerged over six weeks of feeding. In mice on a high-fat, high-sucrose diet, acarbose cut diet-induced weight gain by about a third, while also sharply reducing white fat expansion. On a comparable high-maltose diet, the drug had only a modest effect. When sucrose was replaced with the same amounts of glucose and fructose, the benefit largely disappeared, indicating that the intact disaccharide is central to the mechanism. The findings fit with earlier animal work showing that acarbose can raise short-chain fatty acids in a diet-dependent way, and with clinical studies in people that have reported changes in gut microbial composition in some settings but not others.
Sequencing of mouse faecal samples suggested that the microbiome shift was not random. Acarbose altered the balance of major bacterial groups and enriched organisms including Bacteroides, Akkermansia and Parasutterella in the sucrose-fed animals. Those taxa are associated with pathways that can generate propionate and butyrate, metabolites linked to improved energy regulation. The broader picture is echoed by other recent research: a study in Nature Communications reported that Streptococcus salivarius can counter sucrose-driven obesity in male mice through exopolysaccharides that are fermented into short-chain fatty acids, reinforcing the idea that sugar’s effects depend heavily on which microbes are present and what they are doing. Still, the Japanese team cautions that its findings are based on mice, microbial predictions and model organisms rather than direct human proof. Even so, the work points to a possible future in which an existing diabetes medicine could be paired with dietary sucrose to steer gut bacteria towards metabolic by-products that help limit obesity.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
